Ligand Pharmaceuticals saw a notable increase in its stock price, driven by strategic financial maneuvers.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) experienced a significant uptick in its stock price, rising by 4.17% in yesterday's session. This positive movement follows a recent financing agreement with AvenCell Therapeutics, which has sparked investor interest and optimism about the company's future cash flows.
Advertisement
Ligand Pharmaceuticals Incorporated
LGND.US
LGND.US
Ligand Pharmaceuticals Incorporated
WealthAwesomeMarket cap
$6.01B
P/E
31.0x
52W high
$326.63
52W low
$175.56
1W change
+8.28%
Beta
0.98
Analyst Price Targets
Based on 7 analysts covering LGND · as of Sep 28, 2026
Wall Street analysts forecast LGND stock price to rise 9.6% over the next 12 months.
Consensus
Strong Buy4.57 / 5.00
Avg. Target
C$344.25
+9.6% Upside
Previously C$344.18 on Sep 25, 2026
Current Price
C$314.10
Last close
Analyst Breakdown (7 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LGND's historical volatility
30-Day Vol
25.8%
Annualized
90-Day Vol
34.1%
Annualized
Trend (90d)
+2.8%
Annualized drift
90d Mean
C$317.26
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$315.15 | C$288.34 – C$344.46 |
| 60 trading days | C$316.20 | C$278.84 – C$358.57 |
| 90 trading days | C$317.26 | C$271.98 – C$370.09 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The recent financing agreement with AvenCell Therapeutics is a pivotal move for Ligand, potentially enhancing its royalty revenue and broadening its portfolio of partnered assets, which could lead to sustained growth.
4.17% Increase in Stock Price
Ligand's stock price rose to CA$314.10, reflecting investor confidence in its strategic moves.
Bull case
The financing deal with AvenCell, worth up to $47 million, could significantly boost Ligand's cash flow by adding new royalty streams from AvenCell's CAR-T therapies. Analysts are optimistic about Ligand's royalty aggregation model, suggesting it has strong potential for long-term revenue growth.
Bear case
Despite the positive outlook, Ligand's reliance on partners poses risks. The recent termination of a partnership with Viking Therapeutics highlights potential operational challenges that could impact revenue generation.
Strategic Financing Agreement
Advertisement
Ligand's recent agreement with AvenCell Therapeutics involves a commitment of up to $47 million, which includes $6 million for Series C funding and $41 million tied to clinical milestones. This deal is expected to deepen Ligand's royalty-focused business model, potentially adding significant revenue streams from AvenCell's CAR-T therapy programs.
Market Response and Analyst Outlook
Following the announcement, analysts have shown increased optimism regarding Ligand's future. Barclays initiated coverage with an 'Outperform' rating, citing the company's potential for long-term revenue growth exceeding 20%. The financing agreement is seen as a critical step in expanding Ligand's already diverse portfolio of over 200 partnered assets.
Risks and Considerations
While the recent developments are promising, investors should remain cautious. Ligand's reliance on partner execution and the risk of disputes, as evidenced by the termination with Viking Therapeutics, could pose challenges to its revenue generation. The company's ability to manage these risks will be crucial for sustaining investor confidence moving forward.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
